-

European patent · EP2396333 · In force

Register entry

Publication number
EP2396333
Application number
EP10703945
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Feb 8, 2010
Published
Dec 21, 2011
Granted
Jul 3, 2013
Protection ends at the latest
Feb 7, 2030
Next annual fee due
Feb 28, 2027
IPC classes
C07D 487/04 (2006.01)
A61K 31/519 (2006.01)
A61P 35/00 (2006.01)
Priority
US 151221 P 10.02.2009
US 187766 P 17.06.2009
PCT application
PCT/GB2010/050191 08.02.2010
PCT publication
WO2010/092371 19.08.2010
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Mar 1, 2026

    Change

    Published in Swissreg on 01.03.2026

  2. Mar 1, 2025

    Change

    Published in Swissreg on 01.03.2025

  3. Mar 1, 2024

    Change

    Published in Swissreg on 01.03.2024

  4. Mar 6, 2023

    Change

    Published in Swissreg on 06.03.2023

  5. Jul 3, 2013

    Granted

    Published in Swissreg on 03.07.2013

Parties

Holder

AstraZeneca AB

151 85 Södertälje, SE

Inventor

BRADBURY, Robert, Hugh

Macclesfield Cheshire SK10 4TG, GB

CARR, Gregory, Richard

Macclesfield Cheshire SK10 4TG, GB

RABOW, Alfred, Arthur

Macclesfield Cheshire SK10 4TG, GB

RAO KORUPOJU, Srinivasa

Bangalore 450 024, IN

TUMMA, Harikrishna

Bangalore 450 024, IN

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.